The Australian - 21 February 2011
generic competition and patent expiry are driving pharmaceutical companies to outsource research to universities and other centers, as well as intensifying the use of venture capital . GlaxoSmithKline is entering into long-term contracts with ten academic centers. Eli Lilly is seeking $ 750 million to be allocated to R & D of 20 molecules. In Italy, thanks to a company Internal, Network Ventures, the CNR will be transferred to the Procter & Gamble scientific know-how. In addition to the spin-off systems most used are the assignment of the patent or conclude contracts for joint research.
0 comments:
Post a Comment